BiondVax Pharmaceuticals Ltd. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was ILS 8.902 million compared to ILS 16.087 million a year ago. Net loss was ILS 11.993 million compared to ILS 41.978 million a year ago. Basic loss per share from continuing operations was ILS 0.03 compared to ILS 0.1 a year ago. For the half year, operating loss was ILS 15.660 million compared to ILS 36.136 million a year ago. Net loss was ILS 20.179 million compared to ILS 45.673 million a year ago. Basic loss per share from continuing operations was ILS 0.04 compared to ILS 0.11 a year ago.